Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals Inc.

Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Crinetics Pharmaceuticals on November 6 and set a price target of $90.00. Acco...

Cantor Fitzgerald Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)

Crinetics Pharma (($CRNX)) has held its Q3 earnings call. Read on for the main highlights of the call. Crinetics Pharma’s recent earnings call conv...

Crinetics Pharma’s Positive Earnings Call Highlights PALSONIFY Success

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Crinetics Pharmaceuticals, with a price target of $81.00. ...

H.C. Wainwright Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

Crinetics Pharma ( ($CRNX) ) has released its Q3 earnings. Here is a breakdown of the information Crinetics Pharma presented to its investors. Crin...

Crinetics Pharmaceuticals Reports Positive Launch and Financials

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRNX	$42.86	+2.12%	1.33M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRNX	$42.86	+2.1%	1.33M
3
4
5
6

CRNX

CRNX

Get Crinetics Pharmaceuticals Inc. Data in Excel

Get Crinetics Pharmaceuticals Inc. Data in Excel